GSK-3008348

CAS No. 1629249-33-7

GSK-3008348( GSK3008348 )

Catalog No. M12439 CAS No. 1629249-33-7

GSK-3008348 is a novel potent, selective integrin αvβ6 antagonist for the treatment of idiopathic pulmonary fibrosis (IPF).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 1430 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    GSK-3008348
  • Note
    Research use only, not for human use.
  • Brief Description
    GSK-3008348 is a novel potent, selective integrin αvβ6 antagonist for the treatment of idiopathic pulmonary fibrosis (IPF).
  • Description
    GSK-3008348 is a novel potent, selective integrin αvβ6 antagonist for the treatment of idiopathic pulmonary fibrosis (IPF).Cystic Fibrosis Phase 1 Clinical.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    GSK3008348
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Integrin
  • Recptor
    Integrin
  • Research Area
    Other Indications
  • Indication
    Fibrosis

Chemical Information

  • CAS Number
    1629249-33-7
  • Formula Weight
    487.636
  • Molecular Formula
    C29H37N5O2
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=C(O)C[C@@H](C1=CC=CC(N2N=C(C)C=C2C)=C1)CN3C[C@@H](CCC4=NC5=C(CCCN5)C=C4)CC3
  • Chemical Name
    (3S)-3-[3-(3,5-Dimethyl-1H-pyrazol-1-yl)phenyl]-4-{(3S)-3-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-1-pyrrolidinyl}butanoic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Echistatin, α1 isofo...

    Potent irreversible αVβ3 integrin antagonist (Ki = 0.27 nM). Disrupts attachment of osteoclasts to bone and inhibits bone reabsorption (IC50 = 0.1 nM). Prevents ADP-induced platelet aggregation via inhibition of glycoprotein IIb/IIIa (GpIIb/IIIa, αIIbβ3) receptors (IC50 = 30 nM) in vitro.

  • ER-464195-01

    ER-464195-01 is a specific, orally active inhibitor that inhibits Calreticulin (CRT).

  • RGDS peptide

    RGDS peptide (Arg-Gly-Asp-Ser) is a integrin binding sequence that inhibits integrin receptor function, a tetrapeptide analogue of the cell attachment site of fibronectin.